Elevated serum anti-Saccharomyces cerevisiae antibody accompanied by gut mycobiota dysbiosis as a biomarker of diagnosis in patients with de novo Parkinson’s Disease

Elevated serum anti-Saccharomyces cerevisiae antibody accompanied by gut mycobiota dysbiosis as a biomarker of diagnosis in patients with de novo Parkinson’s Disease
Eur J Neurol. 2023 Jan 24. doi: 10.1111/ene.15711. Online ahead of print.ABSTRACTBACKGROUND: Intestinal inflammation and gut microbiota dysbiosis contribute to Parkinson's Disease (PD) pathogenesis and growing evidence suggests associations between inflammatory bowel diseases (IBD) and PD. Considered as markers of chronic gastrointestinal inflammation, elevated serum anti-Saccharomyces cerevisiae antibody (ASCA) levels, against certain gut fungal component, are related to IBD, but ... read more
Source: PubMedPublished on 2023-01-25By Ying Chen